NCT03409211

Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy subjects. The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be used during this period.

Conditions

• Psoriasis
• Psoriatic Arthritis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	PEVCO	All subjects will receive PEVCO for 6 more weeks.
DIETARY_SUPPLEMENT	Dietary Supplement Capsules without Coconut Oil	All subjects will receive placebo (PBO) for 3 weeks

Timeline

• Start date: 2017-12-12
• Primary completion: 2019-09-30
• Completion: 2019-09-30
• First posted: 2018-01-24
• Last updated: 2020-12-02

Locations

1 site across 1 country: United States